Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Incidence and Risk Factors for Urothelial Carcinoma

October 5th 2022

Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.

Dr. Zhang on Multidisciplinary Approaches in Urothelial Cancer

September 30th 2022

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial Carcinoma

September 30th 2022

The combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelial carcinoma.

Dr. Ornstein on Enfortumab Vedotin in Advanced Urothelial Carcinoma

September 29th 2022

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

September 28th 2022

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

September 26th 2022

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Dr. Aragon-Ching on the Evolving Standard of Care with JAVELIN Bladder 100 in Urothelial Carcinoma

September 23rd 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Dr. Aragon-Ching on the Implications of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

September 21st 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

EphrinB2 Emerges as Targetable Option in Urothelial Carcinoma

September 20th 2022

Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

Enfortumab Vedotin Plus Pembrolizumab Produces Encouraging Responses in Metastatic Urothelial Cancer

September 12th 2022

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

POU2F2 May Be Predictive of Survival Benefit With Maintenance Avelumab in Urothelial Carcinoma

September 11th 2022

The absence of POU2F2, may be predictive of response to maintenance avelumab in patients with advanced or metastatic urothelial carcinoma, according to findings from an analysis peripheral blood samples taken in the JAVELIN Bladder 100 trial.

EphrinB2 Inhibition Plus Pembrolizumab Elicits Promising Activity in Progressive Metastatic Urothelial Carcinoma

August 30th 2022

Dr. Barata on the Role of Maintenance Avelumab in Advanced Urothelial Cancer

August 29th 2022

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

Dr. Desai on the Ideal Patient for Bladder Preservation in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Dr. Desai on the Evolving Standard of Care in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Rucaparib Maintenance Extends PFS in DRD+ Metastatic Urothelial Cancer

August 19th 2022

Maintenance therapy with rucaparib following platinum-based chemotherapy prolonged progression-free survival compared with placebo in patients with DNA repair–deficient-positive, metastatic urothelial cancer.

FDA Accepts BLA for N-803 in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer in Situ

August 1st 2022

The FDA has accepted for review a biologics license application for the IL-15 superagonist N-803 for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits Responses in Advanced Urothelial Cancer

July 26th 2022

Enfortumab vedotin-ejfv plus pembrolizumab induced encouraging responses when used in the frontline treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-based chemotherapy.

Sesen Bio Pauses Clinical Development for Vicineum in BCG-Unresponsive NMIBC

July 18th 2022

The clinical development of Vicineum for use as a potential therapeutic option in patients with high-risk, Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Dr. Desai on Expanding Options for Cisplatin-Ineligible Bladder Cancer

July 13th 2022

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.